Urokinase-Type Plasminogen Activator Binding to Its Receptor Stimulates Tumor Cell Migration by Enhancing Integrin-Mediated Signal Transduction
Lothar Goretzki
Experimental Cell Research, 1999
View PDFchevron_right
Proteomic Identification of Lynchpin Urokinase Plasminogen Activator Receptor Protein Interactions Associated with Epithelial Cancer Malignancy
Pauliina Uitto
Journal of Proteome Research, 2007
View PDFchevron_right
A Region in Urokinase Plasminogen Receptor Domain III Controlling a Functional Association with α5β1 Integrin and Tumor Growth
PRATIMA CHAURASIA
Journal of Biological Chemistry, 2006
View PDFchevron_right
Downregulation of urokinase plasminogen activator receptor expression inhibits Erk signalling with concomitant suppression of invasiveness due to loss of uPAR-β1 integrin complex in colon cancer cells
Michael Quinn
British Journal of Cancer, 2003
View PDFchevron_right
The urokinase plasminogen activator system as a novel target for tumour therapy
Horst Kessler
2000
View PDFchevron_right
Multifaceted Role of the Urokinase- Type Plasminogen Activator (uPA) and its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications
Niaz Mahmood
Frontiers in oncology, 2018
View PDFchevron_right
A Region in Urokinase Plasminogen Receptor Domain III Controlling a Functional Association with 5beta1 Integrin and Tumor Growth
Henrik Gårdsvoll, M. Ploug
Journal of Biological Chemistry, 2006
View PDFchevron_right
The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
Salvatore Sorrenti
Current Cancer Drug Targets, 2009
View PDFchevron_right
Requirement of Receptor-bound Urokinase-type Plasminogen Activator for Integrin αvβ5-directed Cell Migration
S. Strömblad
Journal of Biological Chemistry, 1996
View PDFchevron_right
Urokinase-Receptor/Integrin Complexes Are Functionally Involved in Adhesion and Progression of Human Breast Cancer in Vivo
Clemens Löwik
The American Journal of Pathology, 2001
View PDFchevron_right
Clinical Significance of Urokinase-Type Plasminogen Activator Receptor (uPAR) Expression in Cancer
Charles de Bock
Cheminform, 2004
View PDFchevron_right
Molecular interactions involving urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor, plasminogen activator inhibitor-1 (PAI-1), as new targets for tumour therapy
Albert Remacle
Emerging Therapeutic Targets, 1999
View PDFchevron_right
Tumour Microenvironments Induce Expression of Urokinase Plasminogen Activator Receptor (uPAR) and Concomitant Activation of Gelatinolytic Enzymes
Elin Hadler-olsen, Tuula Salo
PLoS ONE, 2014
View PDFchevron_right
The urokinase plasminogen activator receptor as a gene therapy target for cancer
Peter F Choong
Trends in Biotechnology, 2007
View PDFchevron_right
Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody
Ian McCutcheon
Cancer research, 1993
View PDFchevron_right
Saturation of tumour cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion
Lothar Goretzki
British Journal of Cancer, 1993
View PDFchevron_right
Molecular imaging of the urokinase plasminogen activator receptor: opportunities beyond cancer
Cornelis Sier
EJNMMI Research
View PDFchevron_right
Inhibition of urokinase receptor gene expression and cell invasion by anti-uPAR DNAzymes in osteosarcoma cells
George Murrell
FEBS Journal, 2005
View PDFchevron_right
Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients
Cornelis H Van De Velde
Current Pharmaceutical Design, 2011
View PDFchevron_right
The Murine Receptor for Urokinase-Type Plasminogen Activator Is Primarily Expressed in Tissues Actively Undergoing Remodeling
Leif Lund, M. Ploug
Journal of Histochemistry & Cytochemistry, 2001
View PDFchevron_right
Structure, Function and Expression on Blood and Bone Marrow Cells of the Urokinase‐Type Plasminogen Activator Receptor, uPAR
M. Ploug
Stem Cells, 1997
View PDFchevron_right
The Urokinase Receptor: Involvement in Cell Surface Proteolysis and Cancer Invasion
V. Ellis
Annals of the New York Academy of Sciences, 1992
View PDFchevron_right
Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin αvβ3 induces signal transduction and enhances plasminogen activation
Serge Yarovoi
Thrombosis and Haemostasis, 2006
View PDFchevron_right
Activity-based Protein Profiling Implicates Urokinase Activation as a Key Step in Human Fibrosarcoma Intravasation
Elena Deryugina
Journal of Biological Chemistry, 2006
View PDFchevron_right
Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87)
Viktor Magdolen
Cancer Gene Therapy, 2000
View PDFchevron_right
Quantitative assessment of interaction of urokinase-type plasminogen activator and its receptor (CD87) by use of a solid-phase uPA-ligand binding assay
Lothar Goretzki
Fibrinolysis and Proteolysis, 1997
View PDFchevron_right
Urokinase plasminogen activator receptor (uPAR) expression is reduced by tyrosine kinase inhibitors
Julie Decock
APMIS, 2006
View PDFchevron_right
The Urokinase Plasminogen Activator System: Role in Malignancy
Michael Duffy
Current Pharmaceutical Design, 2004
View PDFchevron_right
Urokinase Plasminogen Activator Receptor (uPA-R): One Potential Characteristic of Metastatic Phenotypes in Minimal Residual Tumor Disease
Markus Heiss
Cancer Research, 1997
View PDFchevron_right
Novel protein interactors of urokinase-type plasminogen activator receptor
Charles de Bock
Biochemical and Biophysical Research Communications, 2010
View PDFchevron_right
A flexible multidomain structure drives the function of the urokinase-type plasminogen activator receptor (uPAR)
Haydyn Mertens, M. Ploug
2012
View PDFchevron_right
Crystals of the urokinase type plasminogen activator variant βc-uPA in complex with small molecule inhibitors open the way towards structure-based drug design
Wolfram Bode
Journal of Molecular Biology, 2000
View PDFchevron_right